Cartesian Therapeutics’ Post

Chimeric Therapeutics, a clinical-stage cell therapy company, announced the reopening of its Phase 1B study on Thursday, focusing on advancing cancer research. This study is a critical step in evaluating the safety and efficacy of their innovative cell therapy treatments. By resuming this trial, Chimeric Therapeutics aims to gather essential data that could lead to groundbreaking advancements in cancer treatment, ultimately improving patient outcomes and offering new hope for those battling the disease. #ChimericTherapeutics #CellTherapy #CancerResearch #Phase1BStudy #ClinicalTrials #CancerTreatment #MedicalResearch #InnovativeTherapies #Biotech #HealthcareInnovation #Oncology #CancerCure #PatientCare #ResearchAndDevelopment #MedicalBreakthroughs #LifeSciences #HealthTech #CancerScience #ClinicalResearch #Biotechnology

MiNK Therapeutics' Q1 report MiNK Therapeutics #Cancer #INKTCellPrograms #OncoDaily #Oncology #Q1Report

Who is as excited as we are to attend the mRNA-Based Therapeutics Summit in #Boston? As part of tomorrow's pre-conference focus day, we are hosting a panel discussion on "Next-generation cell therapies with mRNA technology". Come join us as we share recent successes and challenges of mRNA-based cell therapies to indicate future directions & more. #mRNA #celltherapy

The work at Intellia Therapeutics, Inc. never ceases to amaze me. Dr. Laura Sepp Lorenzino's account of developing CRISPR therapies for liver disease is well worth a gander. As many know, producing large quantities of guide RNA to enable such therapies is easier said than done. If you utilize CRISPR in your therapeutic development program, please consider Oligo Factory as a capable supplier when scaling to IND-enabling studies and beyond. Oligonucleotide Therapeutics Society Laura Sepp Lorenzino: The Promise of CRISPR Therapeutics In Vivo and Cell Therapy Applications - YouTube https://hubs.la/Q021ywQd0

4th International Conference on Lymphocyte Engineering- a very interesting scientific event and great opportunity to refresh friendships:) With Anke Fuchs (Technical University of Dresden) and Marc Martinez- Llordella (Quell Therapeutics)- three members of the "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies" (COST Action). The action that changed a lot and is the starting point for the current projects :) https://lnkd.in/d6EaPD82

Great improvement in the delivery of innovative CAR-T cell therapies to cancer patients

Our #CancerResearch approach is driven by our deep understanding of causal human biology. Leveraging our differentiated research platforms, targeted #ProteinDegradation, #CellTherapy and radiopharmaceutical therapeutics (RPTs), we’re leading the way as we work to advance transformative new treatment options for patients. Explore our approach to cancer research: https://bit.ly/3Rb1R5C #ASCO24

Cypris Therapeutics, Inc. Launches With Breakthrough In Synthetic Chemistry Learn more & get our take 👇 https://lnkd.in/grR8FnKx “We see vast potential in Cypris Therapeutics’ technology not only as a promising opportunity to develop next generation oncology treatments, but as a platform for iterating natural products for other age-related indications where traditional medicinal chemistry approaches have been elusive.” — Kelsey Moody, PhD, MBA, CEO and Founder at Ichor Life Sciences, Inc. “At Cypris Therapeutics, we are driven by a mission to develop life-saving therapies for some of the deadliest and therapeutically challenging diseases. Our technology represents a new frontier in cancer treatment, offering hope to patients who currently have limited options.” — Kyle Parella, PhD, Co-Founder and CEO at Cypris Therapeutics #therapeutics #funding #SoHCNews

In this lecture, Intellia Therapeutics, Inc. will provide an overview of how Intellia is leveraging its CRISPR-based technologies to develop novel, potentially curative therapeutics. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. https://bit.ly/3P0hSJG The company’s in vivo investigational programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s investigational ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. #CRISPR #GenomeEditing #genomesequencing

#Peptide_Cancer_Vaccine Market Insights, Trends & Future Development Status Recorded during 2023-2032 >> https://lnkd.in/g5WgSY7z #Peptide cancer #vaccine is a relatively new type of #cancer vaccine made from #synthetic #peptides for treating and #preventing various types of solid tumors. It can stimulate #tumor-reactive #T #cells and create a T-cell #immune response against the #malignant tumor in the body. Boston Biomedical, Inc., Vaxon Biotech, TapImmune Inc, Sellas, ISA Pharmaceuticals, Generex Biotechnology Corporation, Immatics, OncoTherapy Science Inc (4564), Brightpath Biotherapeutics, Enzo Life Sciences #peptide #cancervaccine #biotechnology #syntheticpeptides #healthcareindustry #medicalscience